NewAmsterdam Pharma (NAMS) Change in Accured Expenses (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Change in Accured Expenses data on file, last reported at -$10.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 108.56% year-over-year to -$10.3 million; the trailing twelve-month figure through Mar 2026 stood at -$2.9 million (down 55.3% YoY), and the FY2025 full-year result was $2.4 million, up 45.2% from the prior year.
• Change in Accured Expenses slipped to -$10.3 million in Q1 2026, from $5.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $9.3 million in Q3 2023 to a low of -$10.3 million in Q1 2026.
• A 4-year average of -$55846.2 and a median of $402000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 431.0% in 2025, while the deepest fall reached 258.65% in 2025.
• Tracing NAMS's Change in Accured Expenses over 4 years: stood at -$5.8 million in 2023, then jumped by 141.3% to $2.4 million in 2024, then jumped by 122.39% to $5.3 million in 2025, then plunged by 294.03% to -$10.3 million in 2026.
• Business Quant data shows NAMS's Change in Accured Expenses at -$10.3 million in Q1 2026, $5.3 million in Q4 2025, and $638000.0 in Q3 2025.